Results 31 to 40 of about 2,693,659 (343)

Should Research Ethics Encourage the Production of Cost-Effective Interventions? [PDF]

, 2016
This project considers whether and how research ethics can contribute to the provision of cost-effective medical interventions. Clinical research ethics represents an underexplored context for the promotion of cost-effectiveness.
A Briggs, A Fleischman, A Rid, AD Paltiel, AJ London, AJ London, AM Garber, AS Kesselheim, C Grady, CC Denny, D Barnbaum, D Mortimer, D Wendler, DA Hyman, DB Resnik, DJ Torgerson, DM Dimichele, DR Buchanan, E Frank, ED Prentice, EE Roughead, EJ Emanuel, EJ Emanuel, EJ Emanuel, EJ Emanuel, EJ Emanuel, F Baylis, FA Lederle, G Yamey, GA Cohen, GR Wilensky, H Grabowski, HF Lynch, HG Frankfurt, HJ Curzer, I Rudan, J Cohen, J Dowie, J Harris, J McMahan, JA Tobert, JC Lindsey, JW Berg, L Bojke, LP Garrison Jr, M Angell, M Limb, MF Drummond, MJ Mehlman, MS Mano, N Daniels, NMP King, NMP King, PA Ubel, PJ Neumann, PJ Neumann, PR Orszag, PR Orszag, PT Menzel, PT Menzel, PT Menzel, R Dresser, RA Epstein, RA Rettig, RA Spinello, RK Lie, RL Fleurence, S Batt, S Joffe, S Palmer, S Thomson, S Woods, SE Weinberger, SK Shah, T Fojo, T Hurka, T Schrecker, TJ Zywicki, U Schüklenk, WC Black, Z Kmietowicz   +80 more
core   +1 more source

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy

ClinicoEconomics and Outcomes Research, 2021
Gianni Ghetti,1 Maria Claudia D’Avella,2 Lorenzo Pradelli1 1Department of Health Economics and Outcome Research, AdRes, Turin, Italy; 2Department of Market Access, Sanofi, Milan, ItalyCorrespondence: Gianni GhettiDepartment of Health Economics and ...
Ghetti G, D'Avella MC, Pradelli L
doaj  

Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [PDF]

, 2008
OBJECTIVE: To compare the cost-effectiveness of eflornithine and melarsoprol in the treatment of human African trypanosomiasis. METHOD: We used data from a Médecins Sans Frontières treatment project in Caxito, Angola to do a formal cost-effectiveness ...
Adam, Blum, Burri, Burri, Chappuis, Commission for Macroeconomics and Health, Edejer, Evans, Goldie, Legros, Louis, Lutumba, Matovu, Murray, Murray, Pepin, Pepin, Pepin, Politi, Priotto, Robays, Schmid, Schmid, Stanghellini   +23 more
core   +2 more sources

Cost-effectiveness analysis of COVID-19 vaccination in Poland

Archives of Medical Science, 2021
Introduction The aim of our study was to assess the potential value of the Comirnaty vaccine (BNT162b2) in Poland. A model was used to estimate patient events, direct medical costs, utilities, and cost-effectiveness for 1 year with and without ...
Katarzyna Orlewska, Waldemar Wierzba, Andrzej Śliwczynski   +2 more
doaj   +1 more source

Diagnostic assessment reviews : is cost-effectiveness analysis helpful or necessary? [PDF]

, 2018
Objective Diagnostic Assessment Reviews are part of the work programme of the National Institute of Health and Care Excellence (NICE) in England to evaluate emergent medical technologies and so ensure timely and consistent adoption within the National
Mason, James, Mistry, Hema
core   +1 more source

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. [PDF]

, 2019
BackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.MethodsTo illustrate ...
Chen, Bingshu E, Dewa, Carolyn S, Hay, Annette, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Jonker, Derek, Leighl, Natasha B, Mittmann, Nicole, O'Callaghan, Chris, Pater, Joseph, Thavorn, Kednapa, Trenaman, Logan, Tu, Dongsheng   +12 more
core   +1 more source

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]

, 2003
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K., Chilcott, J., Claxton, K., Cooper, N.J., McCabe, C., O'Hagan, A., Tappenden, P.   +6 more
core   +2 more sources

Cost-effectiveness analysis. [PDF]

BMJ, 1993
When different health care interventions are not expected to produce the same outcomes both the costs and the consequences of the options need to be assessed. This can be done by cost-effectiveness analysis, whereby the costs are compared with outcomes measured in natural units--for example, per life saved, per life year gained, and per pain or symptom
openaire   +2 more sources

Economic Evaluation Plan (EEP) for A Very Early Rehabilitation Trial (AVERT): An international trial to compare the costs and cost-effectiveness of commencing out of bed standing and walking training (very early mobilization) within 24 h of stroke onset with usual stroke unit care [PDF]

, 2016
Rationale: A key objective of A Very Early Rehabilitation Trial is to determine if the intervention, very early mobilisation following stroke, is cost-effective.
Fiona Ellery, Helen Dewey, Janice M Collier, Julie Bernhardt, Kiu Tay-Teo, Lauren Sheppard, Leonid Churilov, Marj Moodie, null null, Olivia Wu   +9 more
core   +1 more source

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods [PDF]

, 2002
Cost-effectiveness analysis is now an integral part of health technology assessment and addresses the question of whether a new treatment or other health care program offers good value for money.
A H Briggs, B J O’Brien, Department of Health and Aging Commonwealth of Australia, Fieller EC., Gold MR, Ontario Ministry of Health, Pratt JW, Stinnett AA   +7 more
core   +1 more source